Literature DB >> 9744315

Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer.

B Têtu1, J Brisson, H Lapointe, P Bernard.   

Abstract

This study was aimed at testing the hypothesis that the expression of proteases essentially produced by reactive stromal cells (stromelysin-3 [ST3], gelatinase A [GELA], and urokinase [uPA]) is predictive of prognosis in patients with breast cancer. This was a study of patients with node-positive and node-negative breast cancer diagnosed from 1980 to 1986 and with an average of 10 years follow-up. ST3 (665 cases), GELA, and uPA (575 cases each) expression was obtained by in situ hybridization on formalin-fixed, paraffin-embedded material using mRNA antisense probes. ST3 was expressed by 86.6% of the cases; GELA, 77.7%; and uPA, 64.7%. A significant correlation (P < .05) was found between high (more than 10%) ST3 expression and a younger age, lymph node involvement, poor nuclear grade, ductal histology, aneuploidy, and HSP-27 expression. High GELA expression was significantly associated with c-erbB2, ductal histology, and HSP-27 expression. High uPA expression correlated with poor nuclear grade, ductal histology, lack of estrogen and progesterone receptors, and p53 protein accumulation. High level of expression of all three proteases correlated significantly with each other and with cathepsin D expression by reactive stromal cells. By univariate analysis, both ST3 and uPA expression significantly predicted a shorter recurrence-free survival (ST3, P = .0199; uPA, P = .0269). By multivariate analyses, the prognostic significance was lost, most particularly at longer term. This study adds support to the concept that protease expression by reactive stromal cells is related to cancer cell characteristics but that their contribution to cancer progression is marginal.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9744315     DOI: 10.1016/s0046-8177(98)90204-0

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

Review 1.  Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.

Authors:  Elzbieta Skrzydlewska; Mariola Sulkowska; Mariusz Koda; Stanislaw Sulkowski
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

2.  Plasma matrix metalloproteinase 2 levels and breast cancer risk.

Authors:  Sarah A Aroner; Bernard A Rosner; Rulla M Tamimi; Shelley S Tworoger; Nadja Baur; Thomas O Joos; Susan E Hankinson
Journal:  Cancer Epidemiol       Date:  2015-03-19       Impact factor: 2.984

Review 3.  Tissue-dependent induction of apoptosis by matrix metalloproteinase stromelysin-3 during amphibian metamorphosis.

Authors:  Smita Mathew; Liezhen Fu; Takashi Hasebe; Atsuko Ishizuya-Oka; Yun-Bo Shi
Journal:  Birth Defects Res C Embryo Today       Date:  2010-03

Review 4.  Coagulation and cancer: implications for diagnosis and management.

Authors:  M F Loreto ; M De Martinis ; M P Corsi ; M Modesti ; L Ginaldi
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

5.  Mutational analysis of the cleavage of the cancer-associated laminin receptor by stromelysin-3 reveals the contribution of flanking sequences to site recognition and cleavage efficiency.

Authors:  Maria Fiorentino; Liezhen Fu; Yun-Bo Shi
Journal:  Int J Mol Med       Date:  2009-03       Impact factor: 4.101

6.  Differential regulation of cell type-specific apoptosis by stromelysin-3: a potential mechanism via the cleavage of the laminin receptor during tail resorption in Xenopus laevis.

Authors:  Smita Mathew; Liezhen Fu; Maria Fiorentino; Hiroki Matsuda; Biswajit Das; Yun-Bo Shi
Journal:  J Biol Chem       Date:  2009-05-08       Impact factor: 5.157

Review 7.  Regulation of extracellular matrix remodeling and cell fate determination by matrix metalloproteinase stromelysin-3 during thyroid hormone-dependent post-embryonic development.

Authors:  Yun-Bo Shi; Liezhen Fu; Takashi Hasebe; Atsuko Ishizuya-Oka
Journal:  Pharmacol Ther       Date:  2007-08-31       Impact factor: 12.310

Review 8.  Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy.

Authors:  Abdel-Majid Khatib; Géraldine Siegfried; Michel Chrétien; Peter Metrakos; Nabil G Seidah
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

Review 9.  Curcumin: from ancient medicine to current clinical trials.

Authors:  H Hatcher; R Planalp; J Cho; F M Torti; S V Torti
Journal:  Cell Mol Life Sci       Date:  2008-06       Impact factor: 9.261

10.  The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis.

Authors:  Bernard Têtu; Jacques Brisson; Chang Shu Wang; Hélène Lapointe; Geneviève Beaudry; Caty Blanchette; Dominique Trudel
Journal:  Breast Cancer Res       Date:  2006-06-15       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.